The inhibition of cell-cycle-related kinases, which are intrinsic to HCC, has also been shown to weaken cancer immunosuppression by MDSCs, thus further enhancing the blocking effect of PD-L1, making it a potential therapeutic target [136]. This evidence concerns the gene CD274 and cancer.